The nurse explains to a patient with chronic myelogenous leukemia that the therapeutic action of Gleevec (Imatinib) is to:
A) bind directly DNA or RNA to block the aberrant cancer-causing gene product.
B) silence genes that are implicated in causing the growth of cancer causing cells.
C) selectively increase transcription levels of certain genes.
D) promote the replication of healthy genetic material.

Question

Quizplus · Accepted Answer

Imatinib (Gleevec) works by binding to the BCR-ABL tyrosine kinase, an abnormal protein produced by the cancer-causing gene in chronic myelogenous leukemia, thereby inhibiting its activity and blocking the proliferation of cancer cells.

The Nurse Explains to a Patient with Chronic Myelogenous Leukemia